A market that grows even as the total population shrinks

Japan's medical devices market reached JPY 5.996 trillion (USD ~40 billion) in 2023 [MHLW 2024], the world's third-largest after the United States and China. Domestic production stood at JPY 2.67 trillion (+3.6% year-on-year), while imports reached JPY 3.32 trillion (+13.8% year-on-year), confirming a structurally net-importer position [MHLW 2024]. Domestic shipments were JPY 4.87 trillion after netting out JPY 1.13 trillion of exports. What makes Japan's market distinctly resilient is its demand foundation: with 29.3% of the population aged 65 and over — the highest share in the world — device consumption is underwritten by demographic physics rather than the economic cycle [Govt stats 2024].

Japan Medical Devices — Total Market (USD bn)806040200362021402023422025E482027F542028F622030F
Source: MHLW Pharmaceutical & Medical Device Production Statistics 2024; KIRA triangulation and forecast model. USD figures converted from yen at approximate prevailing rates.

Segment growth: where the demographic pull lands

Growth is uneven across the five device segments. Diagnostic imaging holds the largest single-segment share at an estimated USD 12.5 billion in 2025, growing at roughly 5% CAGR as chronic-disease detection volumes rise and AI-augmented reading begins to drive system upgrades [Kira estimates]. In-vitro diagnostics — where domestic players hold genuine global scale — is projected to climb from USD 4.84 billion in 2024 to USD 7.02 billion by 2033, a 4.2% CAGR [secondary segment forecasts]. Orthopedics is the fastest demographically-driven accelerator, with joint-replacement volume scaling almost linearly with the 80-plus cohort now exceeding 10% of the population [Kira estimates]. Cardiovascular devices grow at an estimated 6% CAGR, reflecting both the chronic-disease burden and the expanding therapeutic catheter portfolio of domestic manufacturers such as Terumo [secondary segment forecasts].

The import dependency that amplifies every policy shift

Japan's 55% import dependency is not uniform across the market [Kira estimates]. Domestic manufacturers hold world-scale positions in diagnostic imaging, endoscopy, dialysis consumables, and IVD reagents. The import intensity concentrates in high-margin therapeutic implantables — cardiac rhythm management, coronary stents, structural-heart devices, and orthopedic implants — where US and European multinationals hold dominant shares. This bifurcation means that every yen weakening and every reimbursement revision hits import-led therapeutic categories hardest, creating asymmetric margin pressure on hospital procurement budgets. KIRA estimates that a 10-yen depreciation against the US dollar increases the landed-cost burden on the therapeutic import segment by approximately JPY 50–80 billion annually, before any reimbursement adjustment [Kira estimates].

Methodology note: Total market figures are sourced directly from MHLW Pharmaceutical and Medical Device Production Statistics (calendar year 2023, published 2024). USD conversion uses approximate prevailing rates and should be treated as directional. Segment USD estimates combine MHLW yen-denominated production and trade data with published secondary segment forecasts, triangulated by KIRA analysts. Forward projections (2025E–2030F) assume current reimbursement timelines hold and no major supply-chain disruption; they carry inherent uncertainty and are not audited accounts.